科研之友
微信
新浪微博
Facebook
分享链接
摘要
Amyloid plaques in the extracellular parenchyma mainly consist of amyloid-beta peptides (A beta), one of the pathological hallmarks in Alzheimer's disease (AD). In the present study, we examined neuroinflammation, amyloidogenesis, and memory performance following intracerebral infusions of leukotriene D4 (LTD4) in mice. The results demonstrated that intracerebral infusions of LTD4 (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A beta 1-40 and A beta 1-42 in the hippocampus and cortex through increased activity of beta- and gamma-secretases accompanied with increased expression of amyloid precursor protein (APP). LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-kappa B p65 in the hippocampus and cortex. Pretreatment with pranlukast (115 ng/mouse, intracerebroventricularly), a CysLT(1)R antagonist, blocked LTD4-induced amyloidogenesis, memory deficits. Pranlukast (0.6 mu M) also prevented LTD4 (20 nM)-induced amyloidogenesis in the cultured neurons in vitro. Moreover, LTD4-induced increases in CysLT(1)R and NF-kappa B p65 in the brain were also attenuated by pranlukast These results suggest that LTD4 increases A beta peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of beta- and gamma-secretases via the NF-kappa B pathway. Our findings identify CysLT(1)R signaling as a novel proinflammatory and proamyloidogenic pathway, and suggest a rationale for development of therapeutics targeting the CysLT(1)R in neuroinflammatory diseases such as AD.
